Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27295845 | 0.83 | MEN1 (0.51) | GRM5MAPTCNR2MEN1LMNA | |
| SCHEMBL8545034 | 0.83 | HCAR3 (0.51) | GRM5MAPTCNR2KDM4EMEN1 | |
| SCHEMBL18809363 | 0.83 | NPC1 (0.42) | MAPTMEN1KMT2AIDO1STK17A | |
| Hydrochloric Acid SCHEMBL31473439 | 0.82 | MEN1 (0.50) | GRM5MAPTCNR2MEN1LMNA | |
| SCHEMBL29501822 | 0.80 | MAPT (0.57) | GRM5MAPTIDO1 | |
| SCHEMBL28402729 | 0.80 | MAPT (0.57) | GRM5MAPTIDO1 | |
| SCHEMBL12590968 | 0.80 | MEN1 (0.42) | MAPTMEN1LMNAKMT2A | |
| SCHEMBL21258685 | 0.74 | KMT2A (0.51) | GRM5MAPTMEN1LMNAKMT2A | |
| SCHEMBL29849858 | 0.74 | NPC1 (0.62) | GRM5MAPTKDM4EMEN1LMNA | |
| SCHEMBL4516270 | 0.74 | NPC1 (0.62) | GRM5MAPTKDM4EMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920048-B2 | Substituted pyrimidines for inhibiting Raf kinase activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158686-A1 | Compounds Useful as Raf Kinase Inhibitors | BRAF, RAF1, ARAF | GRM5 4236/4885MAPT 3659/4885CNR2 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.